Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sepulveda

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Transplantation Proceedings|March 28, 2018
Tumor Biology as Predictor of Mortality in Liver Transplantation for Hepatocellular CarcinomaL A Caicedo, A Delgado, M Duque, et al.
Human Brain Mapping|June 13, 2024
Microscopic fractional anisotropy outperforms multiple sclerosis lesion assessment and clinical outcome associations over standard fractional anisotropy tensorF Vivó, E Solana, A Calvi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 9, 2016
New clinical trials regulation in Spain: analysis of royal decree 1090/2015M Martin Jimenez, A Calvo Ferrandiz, J Aparicio Urtasun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphomaV Moreno, J M Sepulveda, M Vieito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Revista De Neurologia|July 13, 2011
[HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]Y Blanco, G Ercilla-González, S Llufriu, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Transplantation Proceedings|March 28, 2018
Tumor Biology as Predictor of Mortality in Liver Transplantation for Hepatocellular CarcinomaL A Caicedo, A Delgado, M Duque, et al.
Human Brain Mapping|June 13, 2024
Microscopic fractional anisotropy outperforms multiple sclerosis lesion assessment and clinical outcome associations over standard fractional anisotropy tensorF Vivó, E Solana, A Calvi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 9, 2016
New clinical trials regulation in Spain: analysis of royal decree 1090/2015M Martin Jimenez, A Calvo Ferrandiz, J Aparicio Urtasun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphomaV Moreno, J M Sepulveda, M Vieito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Revista De Neurologia|July 13, 2011
[HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]Y Blanco, G Ercilla-González, S Llufriu, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M J Clement, Linda Dirven, Marica Eoli, et al.
Pageof 7